Key Drivers
- Cash Cushion
- Operating Losses
- Negative FCF
AIAI Summary
CABA has shifted from a pure “science bet” to a financed execution story: the $150M raise extends runway and supports continued rese-cel progress, but the investable question is now whether tiny, early autoimmune CAR-T signals can be replicated into a scalable regulatory package before dilution, burn, or manufacturing setbacks erode the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Operating Losses
- •Negative FCF
CABA has a strong cash cushion and modest leverage, but zero revenue, persistent operating losses, and negative free cash flow still make the story fundamentally weak.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Overhead resistance
- •Volatility risk
CABA is in a strong last-month recovery with higher lows, but the rebound remains unconfirmed until it clears $4.00-$4.15 and holds above $3.65-$3.69.
Sharp drop from $4.15 to $3.27, then quick rebound, signals choppy volatility
Sentiment & News
Key News Insights:
- •Capital raise
- •Rese-cel progress
- •Relative strength
Cabaletta Bio raised $150 million and reported encouraging rese-cel autoimmune data, reinforcing a more constructive outlook despite recent share volatility.
The new funding extends runway and the improving clinical narrative could support sentiment if upcoming data continue to validate the simplified treatment approach
Similar Companies in Healthcare
Other companies in the same sector with AI ratings